{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:18:07Z","timestamp":1787030287644,"version":"build-2736575974"},"reference-count":38,"publisher":"Innovative Healthcare Institute","issue":"2","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) might increase the risk of major adverse cardiovascular events (MACEs). This study aimed to evaluate the risk of MACE in patients with melanoma after ICI initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a before-after cohort study using claims data from Optum\u2019s deidentified Clinformatics Data Mart Database. We included adult patients with melanoma who received any approved ICI between 2011 and 2021 with a minimum of 12 months of observable data before ICI. The main outcome was time to first MACE (myocardial infarction, coronary revascularization, stroke, heart failure hospitalization) and rate of MACE before and after ICI, ascertained using International Classification of Diseases, 9th\/10th Revision diagnostic codes. Hazard ratio (HR) and incidence rate ratio (IRR) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 4024 patients with ICI-treated melanoma. Mean age was 67.4 years (SD 14.1), 36% were women; 3066 (76.2%) received monotherapy and 958 (23.8%) combination immunotherapy. A total of 160 (4%) patients had a MACE before ICI and 224 (5.6%) after ICI (HR, 1.76; 95% CI, 1.47\u20132.12). MACE rate in the year before ICI was 56.16 per 1000 person-years compared with 80.91 per 1000 person-years the year after ICI (IRR, 1.44; 95% CI, 1.21\u20131.72). Ten cases of myocarditis were observed after ICI, 50% of them had a MACE. Risk factors associated with MACE after ICI were prior MACE, other cardiovascular conditions, hypertension, and older age. Glucocorticoid use was not associated with MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that ICI might increase the risk of MACE in patients with melanoma during the first year after ICI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-24-31","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:11:48Z","timestamp":1744355508000},"page":"132-140","source":"Crossref","is-referenced-by-count":2,"title":["Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors"],"prefix":"10.36401","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-134X","authenticated-orcid":true,"given":"Juan I.","family":"Ruiz","sequence":"first","affiliation":[{"name":"1 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"1 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Palaskas","sequence":"additional","affiliation":[{"name":"2 Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"2 Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"1 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McQuade","sequence":"additional","affiliation":[{"name":"3 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-5797","authenticated-orcid":true,"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"1 Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2025061608264935200_i2590-017X-8-2-132-b01","first-page":"1192762","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Original Research. Front Med (Lausanne)"},{"key":"2025061608264935200_i2590-017X-8-2-132-b02","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b03","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025061608264935200_i2590-017X-8-2-132-b04","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"key":"2025061608264935200_i2590-017X-8-2-132-b05","doi-asserted-by":"crossref","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025061608264935200_i2590-017X-8-2-132-b06","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025061608264935200_i2590-017X-8-2-132-b07","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.22.00369","article-title":"Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program","volume":"40","author":"Naqash","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b08","first-page":"e341","article-title":"Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome","volume":"3","author":"Lopez-Candales","year":"2017","journal-title":"J Nat Sci"},{"key":"2025061608264935200_i2590-017X-8-2-132-b09","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b10","first-page":"19","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in the large arteries of lymphoma patients under 50 years of age","volume":"10","author":"Calabretta","year":"2021","journal-title":"Biology (Basel)"},{"key":"2025061608264935200_i2590-017X-8-2-132-b11","unstructured":"Optum Claims Data\n          . Accessed Nov 2023. www.optum.com\/business\/life-sciences\/real-world-data\/claims-data.html"},{"key":"2025061608264935200_i2590-017X-8-2-132-b12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b13","unstructured":"Table Describing Changes in Codes for NCI Comorbidity Index. Accessed Nov 2023. healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity-table.html"},{"key":"2025061608264935200_i2590-017X-8-2-132-b14","volume-title":"Modern Epidemiology","author":"Hanley","year":"1986"},{"key":"2025061608264935200_i2590-017X-8-2-132-b15","unstructured":"Ipilimumab adjuvant therapy. Melanoma Research Alliance. Accessed Dec 2024. www.curemelanoma.org\/patient-eng\/melanoma-treatment\/adjuvant-therapy\/ipilimumab"},{"key":"2025061608264935200_i2590-017X-8-2-132-b16","unstructured":"FDA grants regular approval to nivolumab for adjuvant treatment of melanoma. US Food and Drug Administration. Accessed Dec 2024. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-nivolumab-adjuvant-treatment-melanoma"},{"key":"2025061608264935200_i2590-017X-8-2-132-b17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/biom.12308","article-title":"Using cumulative sums of martingale residuals for model checking in nested case-control studies","volume":"71","author":"Borgan","year":"2015","journal-title":"Biometrics"},{"key":"2025061608264935200_i2590-017X-8-2-132-b18","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"2025061608264935200_i2590-017X-8-2-132-b19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J Cardiol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2025061608264935200_i2590-017X-8-2-132-b22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025061608264935200_i2590-017X-8-2-132-b23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/CIRCRESAHA.115.306427","article-title":"Adaptive response of T and B cells in atherosclerosis","volume":"118","author":"Ketelhuth","year":"2016","journal-title":"Circ Res"},{"key":"2025061608264935200_i2590-017X-8-2-132-b24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","article-title":"immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications","volume":"79","author":"Vuong","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b25","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"2025061608264935200_i2590-017X-8-2-132-b26","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries","volume":"142","author":"Calabretta","year":"2020","journal-title":"Letter. Circulation"},{"key":"2025061608264935200_i2590-017X-8-2-132-b27","doi-asserted-by":"crossref","first-page":"e007307","DOI":"10.1136\/jitc-2023-007307","article-title":"Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer","volume":"11","author":"Drobni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025061608264935200_i2590-017X-8-2-132-b28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025061608264935200_i2590-017X-8-2-132-b29","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2025061608264935200_i2590-017X-8-2-132-b30","first-page":"23","article-title":"Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study","volume":"8","author":"Wang","year":"2022","journal-title":"Cardiooncology"},{"key":"2025061608264935200_i2590-017X-8-2-132-b31","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.esmoop.2021.100252","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain","year":"2021","journal-title":"ESMO Open"},{"key":"2025061608264935200_i2590-017X-8-2-132-b32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2025061608264935200_i2590-017X-8-2-132-b33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7861\/clinmed.2018-0440","article-title":"Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma","volume":"20","author":"Agarwal","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"2025061608264935200_i2590-017X-8-2-132-b34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2025061608264935200_i2590-017X-8-2-132-b35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"key":"2025061608264935200_i2590-017X-8-2-132-b36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2025061608264935200_i2590-017X-8-2-132-b37","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025061608264935200_i2590-017X-8-2-132-b38","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.amjcard.2019.03.022","article-title":"Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease","volume":"123","author":"Berger","year":"2019","journal-title":"Am J Cardiol"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/132\/3506993\/10.36401_jipo-24-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/132\/3506993\/10.36401_jipo-24-31.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:39Z","timestamp":1765475319000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/2\/article-p132.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,11]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-24-31","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}